Cargando…

Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany

Background Multigene assays are being used increasingly to aid in decision-making about chemotherapy in breast cancer. Here, we present the 21-gene recurrence score (RS) of patients tested in routine clinical practice in Germany. Patients and Methods In a retrospective analysis, 4695 patients with h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walter, Vincent P., Taran, Florin-Andrei, Wallwiener, Markus, Bauer, Armin, Grischke, Eva-Maria, Walter, Christina Barbara, Hahn, Markus, Brucker, Sara Y., Hartkopf, Andreas Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2020
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299682/ https://www.ncbi.nlm.nih.gov/pubmed/32565552 http://dx.doi.org/10.1055/a-1111-8734

Ejemplares similares

Association between 21-gene-assay and detection of disseminated tumor cells in patients with early breast cancer: results from the IRMA trial
por: Volmer, Léa L., et al.
Publicado: (2023)

Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients
por: Hartkopf, Andreas D., et al.
Publicado: (2016)

Recurrence Score(®) Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial
por: Dannehl, Dominik, et al.
Publicado: (2022)

Electrochemotherapy – Supplementary Treatment for Loco-regional Metastasized Breast Carcinoma Administered to Concomitant Systemic Therapy
por: Grischke, Eva-Maria, et al.
Publicado: (2017)

Sequencing for an interdisciplinary molecular tumor board in patients with advanced breast cancer: experiences from a case series
por: Walter, Christina, et al.
Publicado: (2020)

The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy
por: Hartkopf, Andreas Daniel, et al.
Publicado: (2013)

Multidisciplinary breast centres in Germany: a review and update of quality assurance through benchmarking and certification
por: Wallwiener, Markus, et al.
Publicado: (2012)

Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer
por: Walter, Vincent, et al.
Publicado: (2020)

Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial
por: Wallwiener, Markus, et al.
Publicado: (2017)

An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study
por: Matthies, Lina Maria, et al.
Publicado: (2019)

Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients
por: Hartkopf, Andreas D, et al.
Publicado: (2017)

Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center
por: Dannehl, Dominik, et al.
Publicado: (2022)

Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre
por: Matovina, Sabine, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow
por: Volmer, Léa, et al.
Publicado: (2022)

Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry
por: Stefanovic, Stefan, et al.
Publicado: (2017)

Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers
por: Taran, Florin-Andrei, et al.
Publicado: (2018)

The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
por: Wallwiener, Markus, et al.
Publicado: (2010)

Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
por: Wallwiener, Markus, et al.
Publicado: (2015)

Update Breast Cancer 2017 – Implementation of Novel Therapies
por: Lux, Michael P., et al.
Publicado: (2017)

Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer
por: Schütz, Florian, et al.
Publicado: (2019)

Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial
por: Graf, Joachim, et al.
Publicado: (2022)

Certification of breast centres in Germany: proof of concept for a prototypical example of quality assurance in multidisciplinary cancer care
por: Brucker, Sara Y, et al.
Publicado: (2009)

Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer
por: Welslau, Manfred, et al.
Publicado: (2019)

Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel
por: Kolberg, Hans-Christian, et al.
Publicado: (2019)

The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers
por: Schäffler, Henning, et al.
Publicado: (2023)

Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
por: Hartkopf, Andreas D., et al.
Publicado: (2019)

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
por: Huebner, Hanna, et al.
Publicado: (2020)

Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients
por: Krawczyk, Natalia, et al.
Publicado: (2014)

Hospital versus individual surgeon’s performance in laparoscopic hysterectomy
por: Driessen, Sara R. C., et al.
Publicado: (2016)

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
por: Lux, Michael P., et al.
Publicado: (2018)

Measurement of tumour size with mammography, sonography and magnetic resonance imaging as compared to histological tumour size in primary breast cancer
por: Gruber, Ines V, et al.
Publicado: (2013)

The impact of rehabilitation sport on breast cancer-related lymphoedema and quality of life
por: Boeer, Bettina, et al.
Publicado: (2022)

Tumor-Free Resection Margin Distance in the Surgical Treatment of Node-Negative Squamous Cell Cancer of the Vulva Has No Impact on Survival: Analysis of a Large Patient Cohort in a Tertiary Care Center
por: Taran, Florin Andrei, et al.
Publicado: (2023)

Re-augmentation of the Axilla Using a Turn-Over Flap – a New Approach for the Surgical Treatment of Secondary Lymphedema After Breast Cancer
por: Marx, Mario, et al.
Publicado: (2020)

The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer
por: Stefanovic, Stefan, et al.
Publicado: (2020)

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
por: Schneeweiss, Andreas, et al.
Publicado: (2020)

Benchmarking the quality of breast cancer care in a nationwide voluntary system: the first five-year results (2003–2007) from Germany as a proof of concept
por: Brucker, Sara Y, et al.
Publicado: (2008)

Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer
por: Deutsch, Thomas M., et al.
Publicado: (2020)

Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer
por: Fischer, Chiara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ih6pueqom1o5hls0he09kakgg3